2015
Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis
McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH. Sex Differences in Varenicline Efficacy for Smoking Cessation: A Meta-Analysis. Nicotine & Tobacco Research 2015, 18: 1002-1011. PMID: 26446070, PMCID: PMC5942618, DOI: 10.1093/ntr/ntv207.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsSmoking cessationDouble-blind placebo-controlled trialEfficacy of vareniclinePlacebo-controlled trialShort-term outcomesClinical trial dataSex differencesSimilar ratesWeek 52Week 24Women smokersNicotine replacementWeek 12Outcome endpointsTherapeutic responseClinical trialsContinuous abstinenceVarenicline's efficacyVareniclinePlacebo outcomesEqual efficacySex disparitiesEffective FDA
2012
Longitudinal Associations Between Smoking Cessation Medications and Alcohol Consumption Among Smokers in the International Tobacco Control Four Country Survey
McKee SA, Young‐Wolff K, Harrison EL, Cummings KM, Borland R, Kahler CW, Fong GT, Hyland A. Longitudinal Associations Between Smoking Cessation Medications and Alcohol Consumption Among Smokers in the International Tobacco Control Four Country Survey. Alcohol Clinical And Experimental Research 2012, 37: 804-810. PMID: 23240586, PMCID: PMC3610791, DOI: 10.1111/acer.12041.Peer-Reviewed Original ResearchConceptsSmoking cessation medicationsCessation medicationsNicotine replacementAlcohol consumptionInternational Tobacco Control Four Country SurveyFour Country SurveyNicotine replacement therapyReduced alcohol consumptionSmoking statusReplacement therapySmoking cessationMedication effectsMedicationsSmoking behaviorEpidemiological investigationsCountry SurveySmokersAvailable evidenceLongitudinal associationsBaseline drinkingEpidemiological sampleFrequent drinkingTelephone surveyVareniclineSmoking
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attempts
2007
Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration
McKee SA, O’Malley S, Shi J, Mase T, Krishnan-Sarin S. Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. Psychopharmacology 2007, 196: 189-200. PMID: 17912500, PMCID: PMC2862181, DOI: 10.1007/s00213-007-0952-3.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdultAlcohol DrinkingBlood PressureChromatography, High Pressure LiquidDose-Response Relationship, DrugDouble-Blind MethodDrinking BehaviorFemaleHeart RateHumansMaleMiddle AgedMonitoring, PhysiologicNicotineOscillometrySelf AdministrationSelf-AssessmentSkin TemperatureSmoking PreventionSpectrophotometry, UltravioletSurveys and QuestionnairesTime FactorsConceptsTransdermal nicotine replacementNicotine replacementSelf-administration periodPriming drinkHeavy drinkersPatch applicationNicotine deprivationAlcohol responsesNicotine patch conditionPlacebo patch conditionDouble-blind studySystolic blood pressureHeavy drinking smokersPatch conditionsAlcohol drinking behaviorTransdermal patch applicationDrinking behaviorInitiation of drinkingBlood pressurePlacebo patchAdditional drinkDaily smokersTobacco cravingTobacco useHeart rate